会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • FICOLIN-3 ASSAY
    • FICOLIN-3测定
    • US20120101004A1
    • 2012-04-26
    • US13377121
    • 2010-06-09
    • Peter GarredChristian Honoré
    • Peter GarredChristian Honoré
    • C40B30/04G01N33/566
    • G01N33/564G01N2333/4716
    • The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement activation and/or deposition by the detection of a C2, C3, C4 and/or a C5 cleavage product and/or by detecting any of the terminal complement complex components C6, C7, C8 or C9 or 15 the C5b-9 terminal complement complex as such. The present invention also provides assays and kits comprising the methods of the invention.
    • 本发明涉及用于检测补体的凝集素途径的Ficolin-3依赖性活化的方法,用于鉴定Ficolin-3异常的方法,以及筛选Ficolin-3依赖性的任何下游组分的缺陷和/或鉴定异常的方法 所述方法通常包括以下步骤:(a)提供血液,血清,血浆,另一体液或其提取物的样品;(b)使用乙酰化的Ficolin-3配体激活5个补体的凝集素途径。 (b)(任选地)阻止样品激活经典途径和/或替代途径和/或任何非Ficolin-3介导的凝集素途径的活化; (c)乙酰化分子; (d)使所述乙酰化分子10与所述样品接触,条件是允许Ficolin-3与所述乙酰化分子的特异性结合,和(e)检测和定量Ficolin-3与所述乙酰化分子的特异性结合,(f) 通过检测C2,C3,C4和/或C5切割产物和/或通过检测任何终末互补复合物组分C6,C7,C8或C9或15来确定样品中补体活化和/或沉积C5b -9末端补体复合物。 本发明还提供包含本发明方法的测定和试剂盒。
    • 6. 发明申请
    • OPTICAL DEVICE
    • 光学装置
    • US20100139759A1
    • 2010-06-10
    • US12517512
    • 2007-11-23
    • Martin Aagesen
    • Martin Aagesen
    • H01L31/0236H01L31/0368H01L33/00H01L21/20
    • H01L31/0352H01L31/0304H01L33/18Y02E10/544
    • The present invention relates to an optical device and to a method of fabricating the same. In embodiments, the invention relates to a photovoltaic device or solar cell. The optical device comprises a first electrode and a second electrode and an active element disposed between the first and second electrodes. The active element comprising a plurality of semiconducting structures extending in a lengthwise direction from the first electrode and being in contact with the first and second electrodes; the active element comprises an np-junction. For the semiconducting structures, at least a part of the structures is of a general plate or flake shape. In embodiments, the semiconducting structures have at least one characteristic dimension in the nanometer range.
    • 本发明涉及一种光学器件及其制造方法。 在实施例中,本发明涉及光伏器件或太阳能电池。 光学器件包括第一电极和第二电极以及设置在第一和第二电极之间的有源元件。 所述有源元件包括从所述第一电极沿长度方向延伸并与所述第一和第二电极接触的多个半导体结构; 有源元件包括np结。 对于半导体结构,至少一部分结构具有一般板或片状。 在实施例中,半导体结构在纳米范围内具有至少一个特征尺寸。
    • 7. 发明申请
    • COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MALARIA
    • 化合物在疟疾的诊断和治疗中有用
    • US20090324628A1
    • 2009-12-31
    • US10585027
    • 2004-12-28
    • Thor Grundtvig TheanderThomas LavstsenLars HviidMorten A. NielsenPamela A. MagistradoAli SalantiTrine StaalsoAnja Tatiana Ramstedt JensenLouise Jorgensen
    • Thor Grundtvig TheanderThomas LavstsenLars HviidMorten A. NielsenPamela A. MagistradoAli SalantiTrine StaalsoAnja Tatiana Ramstedt JensenLouise Jorgensen
    • A61K39/00A61P37/04
    • C07K14/445A61K39/00Y02A50/412
    • The present invention relates to nucleic acid molecules related to the PFD1235w/MAL7P1.1, PF11_0008, and PF13_0003 gene families as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to endothelial cells, which is characteristic for the pathogenesis of severe malaria (SM). Accordingly, the invention provides pharmaceutical compositions and vaccines, hereunder nucleotide-based vaccines comprising compounds that are related to VAR4, VAR5, and/or VAR6 polypeptides and PFD1235w/MAL7P1.1 PF11_0008, and/or PF13_0003 nucleic acid molecules. The invention further relates to the use of these compounds as medicaments and for the manufacture of compositions, such as immunogenic compositions. In addition, the invention relates to methods of treatment and prevention of severe malaria wherein these methods are based on the nucleic acid molecules and polypeptides of the invention. As these compounds can also be used as biotechnological tools the invention provides in vitro diagnostic methods and kits comprising reagents and IgGs/antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR4, VAR5, and/or VAR6 dependent adhesion to endothelial cells and agent capable of interacting with VAR4, VAR5, and/or VAR6. Finally, a method for identifying polypeptides, which will induce a specific IgG/antibody response upon administration to a subject is provided by the invention.
    • 本发明涉及与PFD1235w / MAL7P1.1,PF11_0008和PF13_0003基因家族相关的核酸分子以及由这些核酸分子编码的氨基酸序列,涉及它们介导感染的红细胞与内皮粘附的作用 细胞,这是严重疟疾(SM)发病机制的特征。 因此,本发明提供药物组合物和疫苗,以下基于核苷酸的疫苗包含与VAR4,VAR5和/或VAR6多肽和PFD1235w / MAL7P1.1 PF11_0008和/或PF13_0003核酸分子相关的化合物。 本发明还涉及这些化合物作为药物和制备组合物如免疫原性组合物的用途。 此外,本发明涉及治疗和预防严重疟疾的方法,其中这些方法基于本发明的核酸分子和多肽。 由于这些化合物也可用作生物技术工具,本发明提供了体外诊断方法和试剂盒,其中包括用于此类方法的试剂和IgG /抗体。 本发明还涉及鉴定能够调节VAR4,VAR5和/或VAR6对内皮细胞和能够与VAR4,VAR5和/或VAR6相互作用的试剂依赖性粘附的试剂的方法。 最后,本发明提供了鉴定多肽的方法,所述多肽在给予受试者时将诱导特异性IgG /抗体应答。